CEO
Intract Pharma
London, England, United Kingdom
Dr Yadav did his PhD from University College London where he pioneered the research to explore ways to deliver monoclonal antibodies orally to the small and large intestine as a potential oral treatment for GI and systemic inflammatory and immunology indications. He headed R&D at Intract Pharma for 5 yrs inventing a proprietary delivery platform to allow stabilization of antibodies in the GI that allows systemic delivery of antibody therapeutics and has been the CEO of Intract for the last 2 yrs.
Disclosure information not submitted.
Thursday, July 11, 2024
3:30 PM – 5:30 PM CET
